# Program 1 Architecture Review Track Phase D - Conceptual Read-Only Reference Boundary and Non-Mutation Model

Status: documentation-only, synthetic-only, non-production, non-runtime, pre-implementation, conceptual read-only reference review. Not an implementation authorization, not a read-only runtime authorization, and not a data-access authorization.

## Purpose

Program 1 Architecture Review Track Phase D defines the conceptual read-only reference boundary for Program 1 and records a strict non-mutation model.

Phase D follows Architecture Review Track Phase A, Phase B, and Phase C. It is not Phase Z+1 and is not a return to the Phase V-Z governance/prototype sequence.

Program 1 remains in pre-implementation hold.

## Track continuity

Phase A established the synthetic-only architecture boundary. Phase B established conceptual module separation and prohibited coupling paths. Phase C established conceptual data-flow and synthetic boundary traces. Phase D narrows the next architecture question: read-only is only a future conceptual reference category and does not authorize operational access or mutation.

## Scope

- Conceptual read-only reference model.
- Strict non-mutation model.
- Prohibited read access paths.
- Prohibited write-back and mutation paths.
- Read-only vs operational access distinction.
- Synthetic reference trace matrix.

## Non-scope

Phase D does not add runtime code, tests, helpers, scripts, imports, services, database migrations, API endpoints, UI flows, schedulers, task runners, integrations, data connectors, real-data ingestion, PHI/PII processing, read-only runtime access, database queries, EHR/EMR access, runtime auth/authz/RBAC, runtime audit logging, patient messaging, appointment mutation, workflow enforcement, Task engine, Outcome Evidence, clinical write workflows, approval/clearance/override runtime capability, production-readiness claim, or go-live authorization.

## Safety boundaries

Phase D is documentation-only, synthetic-only, non-production, non-runtime, pre-implementation, conceptual only, not an implementation authorization, not a production-readiness review, not a clinical deployment review, not a read-only runtime authorization, and not a data-access authorization.

Phase D does not approve production use, real patient data, PHI/PII processing, live clinical deployment, clinical validation, operational clearance, go-live, runtime implementation, runtime read-only access, runtime data flow, database queries, EHR/EMR access, patient record viewing, real-data inspection, write-back behavior, appointment mutation, patient messaging, or approval/clearance/override behavior.

## Phase A/B/C input summary

Phase A established synthetic-only architecture boundaries, permitted future discussion areas, prohibited runtime paths, data classification preview, read-only vs write-capable conceptual distinction, human-in-the-loop responsibility preview, and a future approval dependency map.

Phase B established conceptual module separation, the synthetic documentation layer boundary, future read-only layer boundary, future clinical review layer boundary, prohibited write-capable layer boundary, prohibited patient communication boundary, prohibited appointment mutation boundary, deferred security/audit/authorization layer, and prohibited coupling map.

Phase C established the synthetic entity model, conceptual data-flow model, allowed synthetic trace paths, prohibited real-data flow paths, read-only conceptual flow boundary, write-back and mutation prohibition trace, security/audit/auth conceptual flow limits, and boundary trace matrix.

## Conceptual read-only reference model

Read-only is a future conceptual reference category only. It may be discussed only as documentation.

It must not create runtime access, database queries, EHR/EMR reads, patient record viewing, appointment record viewing, production data inspection, PHI/PII access, audit log inspection, authorization event inspection, or patient message inspection.

## Non-mutation model

Non-mutation is a strict conceptual boundary. Program 1 must not currently create, update, delete, transmit, route, assign, approve, override, clear, validate, deploy, or enforce any clinical or operational object.

Prohibited mutation targets include patient profile, patient record, encounter, clinical note, diagnosis, treatment plan, medication instruction, patient instruction, appointment, appointment status, queue position, staff task, patient message, audit event, authorization state, approval state, override state, outcome evidence record, and workflow state.

## Prohibited read access paths

| Source | Prohibited target | Why prohibited | Current decision | Future review dependency before reconsideration |
| --- | --- | --- | --- | --- |
| EHR/EMR | Program 1 | Would create clinical system access | Prohibited | Real-data, security, clinical safety, and production governance review |
| Production database | Program 1 | Would create production data access | Prohibited | Production governance and security architecture review |
| Patient portal | Program 1 | Would create patient communication or portal data access | Prohibited | Patient communication, privacy/legal, and security review |
| Appointment system | Program 1 | Would create scheduling record access | Prohibited | Appointment governance and security review |
| Staff workflow system | Program 1 | Would create operational workflow access | Prohibited | Workflow governance and security review |
| Real clinical notes | Program 1 | Would create clinical data processing | Prohibited | Clinical safety, privacy/legal, and real-data review |
| Real lab/imaging/endoscopy data | Program 1 | Would create clinical data processing | Prohibited | Clinical safety, privacy/legal, and real-data review |
| Real audit logs | Program 1 | Would create audit data inspection | Prohibited | Audit/security architecture review |
| Real authorization logs | Program 1 | Would create runtime authorization data access | Prohibited | Security architecture review |
| Real patient messages | Program 1 | Would create patient communication data access | Prohibited | Patient communication and privacy/legal review |
| PHI/PII store | Program 1 | Would create PHI/PII processing | Prohibited | PHI/PII processing approval and privacy/legal review |

## Prohibited write-back and mutation paths

| Prohibited target | Mutation risk | Current decision | Future review dependency |
| --- | --- | --- | --- |
| Program 1 -> EHR/EMR | Clinical system write-back | Prohibited | Clinical safety, security, and implementation authorization |
| Program 1 -> production database | Production data mutation | Prohibited | Production governance and implementation authorization |
| Program 1 -> appointment system | Scheduling mutation | Prohibited | Appointment governance review |
| Program 1 -> patient portal | Patient-facing output | Prohibited | Patient communication and privacy/legal review |
| Program 1 -> staff workflow system | Workflow enforcement | Prohibited | Workflow governance review |
| Program 1 -> patient messaging system | Patient communication | Prohibited | Patient communication governance |
| Program 1 -> audit event store | Runtime audit capture | Prohibited | Audit/security architecture review |
| Program 1 -> authorization state | Runtime access grant or denial | Prohibited | Security architecture review |
| Program 1 -> approval/override state | Approval or override capability | Prohibited | Governance authorization; no automatic approval |
| Program 1 -> clinical note | Clinical write-path | Prohibited | Clinical accountability review |
| Program 1 -> diagnosis | Diagnosis writing | Prohibited | Clinical safety review |
| Program 1 -> treatment plan | Treatment execution | Prohibited | Clinical safety review |
| Program 1 -> task assignment | Task engine or workflow activation | Prohibited | Workflow governance review |
| Program 1 -> outcome evidence record | Outcome Evidence activation | Prohibited | Outcome governance review |

## Read-only vs operational access distinction

Read-only concept is documentation-only. Operational access means connection to real systems or records.

Phase D does not permit operational access, read-only runtime integration, clinical use, or production-readiness claims.

## Synthetic reference trace matrix

| Reference concept | Allowed in Phase D | Prohibited in Phase D | Data class allowed | Runtime status | Mutation status | Future dependency | Current decision |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Synthetic patient reference | Text-only reference | Real patient record viewing | Synthetic only | None | None | Future authorization for any expansion | Allowed as docs only |
| Synthetic encounter reference | Text-only reference | Real encounter access | Synthetic only | None | None | Future authorization for any expansion | Allowed as docs only |
| Synthetic finding reference | Text-only reference | Real clinical finding access | Synthetic only | None | None | Future authorization for any expansion | Allowed as docs only |
| Synthetic appointment reference | Prohibition discussion | Appointment system access or mutation | Synthetic only | None | Prohibited | Appointment governance review | Allowed as docs only |
| Synthetic message reference | Prohibition discussion | Patient message access or sending | Synthetic only | None | Prohibited | Patient communication governance | Allowed as docs only |
| Synthetic clinician review reference | Human review concept | Clinical deployment or validation | Synthetic only | None | None | Clinical safety review | Deferred |
| Synthetic audit concept | Deferred concept | Audit capture or audit log inspection | Synthetic only | Not implemented | Prohibited | Audit/security review | Deferred |
| Synthetic authorization concept | Deferred concept | Runtime auth/authz/RBAC | Synthetic only | Not implemented | Prohibited | Security architecture review | Deferred |
| Future read-only reference concept | Conceptual discussion | Runtime read-only access | Synthetic only | Not implemented | None | Read-only authorization and validation | Deferred |
| Operational read access | Not allowed | Real system or record connection | None | Prohibited | None | Explicit future authorization | Prohibited |
| Write-capable operation | Not allowed | Any mutation/writeback | None | Prohibited | Prohibited | Separate future authorization | Prohibited |
| Production deployment concept | Boundary discussion only | Deployment automation or go-live | None | Prohibited | Prohibited | Production governance review | Prohibited |

## Explicit non-approval statement

Phase D does not approve implementation, production use, real-data use, PHI/PII processing, clinical deployment, go-live, runtime data flow, read-only runtime access, database access, EHR/EMR access, patient record viewing, operational access, write-back behavior, runtime authorization, runtime audit logging, patient messaging, appointment mutation, workflow enforcement, clinical write workflows, or approval/clearance/override capability.

## Next-step decision

Recommended next phase: `Program 1 Architecture Review Track Phase E - Human-in-the-Loop Responsibility and Clinical Accountability Boundary`.

If opened, Phase E should remain documentation-only and synthetic-only. Phase E must not introduce runtime implementation, clinical decision execution, autonomous diagnosis, autonomous treatment, patient messaging, or workflow enforcement.

## Closure statement

Architecture Review Track Phase D closes with Program 1 still in pre-implementation hold. No runtime read-only access, operational access, real-data ingestion, PHI/PII processing, write-back behavior, mutation behavior, production use, clinical deployment, approval/clearance/override capability, or go-live authorization is created.
